Research advances in targeted therapy for gallbladder carcinoma
10.3969/j.issn.1001-5256.2023.12.032
- VernacularTitle:胆囊癌的靶向治疗研究进展
- Author:
Liwen DU
1
;
Jiansheng LIU
2
Author Information
1. Shanxi Medical University， Taiyuan， 030001， China
2. Department of Hepatobiliary and Pancreatic Surgery， The First Hospital of Shanxi Medical University， Taiyuan 030001， China
- Publication Type:Review
- Keywords:
Gallbladder Neoplasms;
Signal Transduction;
Therapeutics
- From:
Journal of Clinical Hepatology
2023;39(12):2965-2969
- CountryChina
- Language:Chinese
-
Abstract:
Gallbladder carcinoma （GBC） is a type of malignant tumor with an extremely poor prognosis， and at present， surgical operation is the most effective treatment method for this disease. Unfortunately， due to a lack of typical symptoms in the early stage， most patients have progressed to the advanced stage at the time of confirmed diagnosis and lost the opportunity for radical surgery. Among the currently available adjuvant treatments， targeted therapy has higher specificity and fewer side effects and has improved the prognosis of a variety of malignancies. With reference to the latest research advances in targeted therapy for GBC， this article reviews the current research status， potential targets， and targeted medications of targeted therapy for GBC， in order to provide a reference for the clinical treatment of GBC patients.
